9342 Federal Register / Vol. 72, No. 40 / Thursday, March 1, 2007 / Notices 

1FDA has verified the Web site addresses, but 

FDA is not responsible for any subsequent changes 

to the Web sites after this document publishes in 

the Federal Register. 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): NIOSH 

Occupational Safety and Health Project 

Grants, Program Announcement 

Number (PAR) 06–484 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 8:30 a.m.–5:30 p.m., March 

15, 2007 (Closed). 

Place: Residence Inn, 1456 Duke Street, 

Alexandria, VA 22314, telephone 703–548–

5474. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The SEP meeting 

will include the review, discussion, and 

evaluation of applications received in 

response to ‘‘NIOSH Occupational Safety and 

Health Project Grants,’’ PAR 06–484. The 

applications being reviewed include 

information of a confidential nature, 

including personal information concerning 

individuals associated with the applications. 

This Federal Register Notice is being 

published on less than 15 calendar days 

notice to the public (41 CFR 102–3.150(b)), 

for the following reason: The cancellation of 

a preparatory meeting scheduled for January 

16th due to inclement weather caused the 

late publication of this notice. Convening the 

preparatory meeting was necessary before 

this meeting could be scheduled. The 

preparatory meeting occurred on February 

20–21, 2007, which enabled the program to 

finalize plans for this meeting. 

For Further Information Contact:Charles 

Rafferty, Ph.D., Designated Federal Officer, 

1600 Clifton Road NE, Atlanta, GA 30333, 

telephone 404–498–2582. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 26, 2007. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–3653 Filed 2–28–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

The Essentials of Food and Drug 

Administration Medical Device 

Regulations: A Primer for 

Manufacturers and Suppliers; Public 

Seminar 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public seminar. 

SUMMARY: The Food and Drug 

Administration’s (FDA’s) Center for 

Devices and Radiological Health and 

Office of Regulatory Affairs, in 

cooperation with AdvaMed’s Medical 

Technology Learning Institute, is 

announcing a series of three seminars 

on FDA medical device regulations. 

These 2-day seminars, which are 

designed to address the training needs 

of start up and small device 

manufacturers and their suppliers, will 

include both industry and FDA 

perspectives and a question and answer 

period. 

Dates: The seminars are planned for 

the following dates: 

1. March 15 and 16, 2007, in Irvine, 

CA 92614. Details about dates are 

posted on AdvaMed’s Web site at: 

www.advamed.org/irvine.1

2. May 22 and 23, 2007, in Lakewood, 

CO 80228. Details about dates are 

posted on AdvaMed’s Web site at: 

www.advamed.org/denver. 

3. June 6 and 7, 2007, in Pittsburgh, 

PA, Details about dates are posted on 

AdvaMed’s Web site at: 

www.advamed.org/pittsburgh. 

Locations: The seminars are planned 

for the following locations: 

1. March 15 and 16, 2007, Crown 

Plaza Hotel, 17941 Von Karman, Irvine, 

CA 92614. Details about location sites 

are posted on AdvaMed’s Web site at: 

www.advamed.org/irvine. 

2. May 22 and 23, 2007, Sheraton 

Denver West, 360 Union Blvd., 

Lakewood, CO 80228. Details about 

location sites are posted on AdvaMed’s 

Web site at: www.advamed.org/denver. 

3. June 6 and 7, 2007, Hilton 

Pittsburgh, 600 Commonwealth Pl., 

Pittsburgh, PA 15222, 

www.HiltonPittsburgh.com. Details 

about location sites are posted on 

AdvaMed’s Web site at: 

www.advamed.org/pittsburgh. 

Contact: For FDA: William Sutton, 

Division of Small Manufacturers, 

International and Consumer Assistance, 

Center for Devices and Radiological 

Health (HFZ–220), 1350 Piccard Dr., 

Rockville, MD 20850, 800–638–2041, 

ext. 125, FAX: 240–276–3151, e-mail: 

William.sutton@fda.hhs.gov. 

For AdvaMed: Dia Black, 202–434–

7231, FAX: 202–783–8750, e-mail: 

DBlack@AdvaMed.org. 

Registration: The registration fee for 

FDA employees is waived. Send 

registration information (including 

name, title, firm name, address, 

telephone, and fax number) and the 

registration fee of $495 per person to 

AdvaMed contact Dia Black, 202–434–

7231, FAX: 202–783–8750. Payment 

forms accepted are major credit card 

(MasterCard, Visa, or American Express) 

or company check. If you wish to pay 

by check, contact Dia Black at: 

DBlack@AdvaMed.org. 

To register via the Internet, go to 

www.AdvaMed.org. The latest 

information on dates/venue sites will be 

posted on this Web site at: 

www.advamed.org/irvine, 

www.advamed.org/denver, and 

www.advamed.org/pittsburgh (FDA has 

verified the Web site addresses, but is 

not responsible for changes to the Web 

sites after this document publishes in 

the Federal Register). 

For more information on the meeting, 

or for questions on registration, contact 

Dia Black (see Contact). 

Attendees are responsible for their 

own accommodations. For further hotel 

information and driving directions, go 

to the registration Web site. 

The registration fee will be used to 

offset the expenses of hosting the 

conference, including meals (breakfasts 

and a lunch), refreshments, meeting 

rooms, and training materials. It also 

includes a networking reception on the 

evening of the first day of each seminar. 

Space is limited; therefore, interested 

parties are encouraged to register early. 

There will be no onsite registration. 

If you need special accommodations 

due to a disability, please contact Dia 

Black (see Contact) at AdvaMed at least 

7 days in advance of the seminar. 

SUPPLEMENTARY INFORMATION: The 

‘‘Essentials of FDA Medical Device 

Regulations: A Primer for Manufacturers 

and Suppliers’’ seminar helps fulfill the 

Department of Health and Human 

Services’ and FDA’s important mission 

to protect the public health by educating 

new entrepreneurs on the essentials of 

FDA device regulations. FDA has made 

education of the medical device 

community a high priority to assure the 

quality of products reaching the 

marketplace and to increase the rate of 

voluntary industry compliance with 

regulations. 


rmajette on PROD1PC67 with NOTICES
Federal Register / Vol. 72, No. 40 / Thursday, March 1, 2007 / Notices 9343 

The seminar helps to implement the 

objectives of section 903 of the Federal 

Food, Drug, and Cosmetic Act (21 U.S.C. 

393) and the FDA Plan for Statutory 

Compliance, which includes working 

more closely with stakeholders and 

ensuring access to needed scientific and 

technical expertise. The seminar also 

furthers the goals of the Small Business 

Regulatory Enforcement Fairness Act 

(Public Law 104–121) by providing 

outreach activities by Government 

agencies directed at small businesses. 

The following topics, as well as 

others, will be discussed at the seminar: 

• Doing business in a regulated 

industry; 

• Organizational structure of FDA; 

• Overview of the quality system 

regulation; 

• Design controls; 

• Documents, records, and change 

control; 

• Purchasing controls and acceptance 

activities; 

• Production and process control; 

• Corrective and preventive actions; 

• Complaints, medical device reports, 

corrections, and recalls; 

• Compliance issues; 

• Management responsibility; 

• Interacting with FDA—Where do 

you go for assistance? 

• General question and answer 

session; 

• Manufacturers and suppliers—the 

chain regulatory responsibility; 

• Reimbursement of medical 

technology; 

• The AdvaMed code of ethics; and 

• Fraud and abuse. 

Dated: February 23, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–3619 Filed 2–28–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, and/or contract proposals, 

the disclosure of which constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, ‘‘Early 

Diagnosis Using Nanotechnology-Based 

Imaging & Sensing’’ and ‘‘Multifunctional 

Therapeutics ‘‘Based on Nanotechnology’’. 

Date: March 14, 2007. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Marriott Bethesda, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Joyce C. Pegues, PhD., 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 7149, 

Bethesda, MD 20892, 301/594–1286, 

peguesj@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Community Networks Program. 

Date: March 22–23, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Bratin K. Saha, PhD., 

Scientific Review Administrator, Program 

Coordination and Referral Branch, Division 

of Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8041, 

Bethesda, MD 20892, (301) 402–0371. 

sahab@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Prevention, 

Control and Population Science SEP. 

Date: March 28, 2007. 

Time: 10 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Conference Room 210, 

Bethesda, MD 20892, (Telephone Conference 

Call). 

Contact Person: Jeannette F. Korczak, PhD., 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Blvd., Room 

8115, Bethesda, MD 20892, 301–496–9767. 

korczakj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS). 

Dated: February 21, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–923 Filed 2–28–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders, 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, Blueprint 

K18—Neurodegeneration. 

Date: March 16, 2007. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Christine A. Livingston, 

PhD, Scientific Review Administrator, 

Division of Extramural Activities, National 

Institutes of Health/NIDCD, 6120 Executive 

Blvd.—MSC 7180, Bethesda, MD 20892, 

(301) 496–8683, livingsc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, 

HHS). 

Dated: February 21, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–924 Filed 2–28–07; 8:45 am] 

BILLING CODE 4140–01–M 


rmajette on PROD1PC67 with NOTICES